{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:53:37Z","timestamp":1792011217236,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019621","name":"Ascentage Pharma Group International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.blre.2026.101436","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:08Z","timestamp":1790867108000},"page":"101436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey"],"prefix":"10.1016","author":[{"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101436_bb0005","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35832","article-title":"Olverembatinib in chronic myeloid leukemia: review of historical development, current status, and future research","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101436_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3311","article-title":"Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: global implications","volume":"42","author":"Polverelli","year":"2024","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0020","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/bjh.70193","article-title":"Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: a population-based study","volume":"207","author":"Chen","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101436_bb0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2years of treatment with tyrosine kinase inhibitor","volume":"98","author":"Bidikian","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2026.101436_bb0035","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000524284","article-title":"Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia: results from a population-representative german claims data analysis","volume":"45","author":"Saussele","year":"2022","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.blre.2026.101436_bb0045","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101436_bb0055","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0060","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","article-title":"Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI","volume":"35","author":"Richter","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0070","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1182\/blood-2024-208569","article-title":"Early predictors of treatment-free remission in chronic myeloid leukemia","volume":"144","author":"Farhat","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0075","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2024-199242","article-title":"A more rapid initial decline of bcr::abl1 transcripts and longer treatment duration with improvement of treatment-free remission rate after discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0080","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101436_bb0085","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0090","first-page":"152","article-title":"SUSTRENIM trial: sustained deep molecular response and TFR rate in the long-term follow-up","volume":"8","author":"Breccia","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2026.101436_bb0095","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0100","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0105","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41375-025-02796-z","article-title":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint","volume":"40","author":"Castagnetti","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.2024026310","article-title":"The evolution of treatment-free remission","volume":"145","author":"Hughes","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0120","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0125","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101436_bb0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","article-title":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","volume":"39","author":"Lipton","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101436_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03262214","article-title":"Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations","volume":"16","author":"Razga","year":"2012","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.blre.2026.101436_bb0145","series-title":"NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. Version 2.2024","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"10.1016\/j.blre.2026.101436_bb0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.2023022538","article-title":"BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib","volume":"144","author":"Leyte-Vidal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0155","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","article-title":"The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib","volume":"38","author":"Leske","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0160","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101436_bb0165","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101436_bb0175","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101436_bb0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101436_bb0185","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/jrh.70028","article-title":"Living with chronic myelogenous leukemia in rural communities: exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach","volume":"41","author":"Sheng","year":"2025","journal-title":"J Rural Health"},{"key":"10.1016\/j.blre.2026.101436_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106734","article-title":"No margin for non-adherence: probabilistic Kaplan-Meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)","volume":"111","author":"Obeng-Kusi","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101436_bb0200","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-025-01242-8","article-title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","volume":"15","author":"Busque","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101436_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-026-01527-6","article-title":"Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms","volume":"16","author":"Haddad","year":"2026","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101436_bb0215","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7116","article-title":"Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors","volume":"22","author":"Haddad","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2026.101436_bb0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clml.2025.10.001","article-title":"SOHO state of the art updates and next questions | choosing the best frontline bcr::abl1 tyrosine kinase inhibitor in chronic myeloid leukemia-how to define the treatment value?","volume":"26","author":"Haddad","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101436_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021662","article-title":"Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"12","author":"Yoshifuji","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0230","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.blre.2026.101436_bb0235","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2478\/folmed-2018-0030","article-title":"Mutations associated with imatinib mesylate resistance: review","volume":"60","author":"Linev","year":"2018","journal-title":"Folia Med (Plovdiv)"},{"key":"10.1016\/j.blre.2026.101436_bb0240","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101436_bb0245","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0255","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40278-021-88206-1","volume":"1836","year":"2021","journal-title":"React Wkly"},{"key":"10.1016\/j.blre.2026.101436_bb0260","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0265","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0270","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101436_bb0275","first-page":"121","article-title":"Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance","volume":"1","author":"Martinelli","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.blre.2026.101436_bb0280","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0285","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0290","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0295","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0300","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0305","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0310","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2019-128761","article-title":"Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis","volume":"134","author":"Hughes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0320","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101436_bb0325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101436_bb0330","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0335","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0340","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101436_bb0350","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101436_bb0355","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101436_bb0360","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50mg\/day versus standard-dose dasatinib 100mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0365","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/21678707.2015.1036027","article-title":"Bosutinib for the treatment of Philadelphia chromosome-positive leukemias","volume":"3","author":"Varallo-Rodriguez","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.blre.2026.101436_bb0370","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101436_bb0375","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0380","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/s41375-024-02372-x","article-title":"Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial","volume":"38","author":"Gambacorti-Passerini","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0390","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0395","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0400","series-title":"Prescribing information","author":"Bosulif.","year":"2024"},{"key":"10.1016\/j.blre.2026.101436_bb0405","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0410","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0415","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/ajh.27355","article-title":"Ponatinib-review of historical development, current status, and future research","volume":"99","author":"Kantarjian","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0420","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0425","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0430","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0435","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101436_bb0440","series-title":"Poster presented at: 2014 ASCO annual meeting; May 30\u2013June 3","article-title":"Clinical impact of dose modification and dose intensity on response to ponatinib in patients with Philadelphia chromosome-positive leukemias","author":"Hochhaus","year":"2014"},{"key":"10.1016\/j.blre.2026.101436_bb0445","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1182\/blood.V124.21.4546.4546","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"124","author":"Knickerbocker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0450","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.26852","article-title":"The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors","volume":"98","author":"Jabbour","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101436_bb0455","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14656566.2022.2064742","article-title":"Ponatinib for the treatment of adult patients with resistant or intolerant chronic-phase chronic myeloid leukemia","volume":"23","author":"Haddad","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2026.101436_bb0460","doi-asserted-by":"crossref","first-page":"103675","DOI":"10.1016\/j.htct.2024.04.124","article-title":"Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: a review of management strategies","volume":"47","author":"Sacha","year":"2025","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.blre.2026.101436_bb0465","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41375-025-02578-7","article-title":"Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: phase 1 final results","volume":"39","author":"Hochhaus","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0470","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1182\/bloodadvances.2025016042","article-title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","volume":"9","author":"Mauro","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101436_bb0475","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia. Reply","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101436_bb0480","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2025029210","article-title":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial","volume":"147","author":"Cortes","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0485","series-title":"Prescribing information","author":"Scemblix.","year":"2025"},{"key":"10.1016\/j.blre.2026.101436_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740529","article-title":"Evaluation of CML TKI induced cardiovascular toxicity and development of potential rescue strategies in a zebrafish model","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2026.101436_bb0495","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.blre.2026.101436_bb0500","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0505","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0510","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2016.353","article-title":"Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors","volume":"31","author":"Lee","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101436_bb0515","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0525","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","article-title":"Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial","volume":"11","author":"Jabbour","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2026.101436_bb0530","series-title":"Prescribing information","author":"Iclusig","year":"2024"},{"key":"10.1016\/j.blre.2026.101436_bb0535","series-title":"Prescribing information","author":"Tasigna","year":"2024"},{"key":"10.1016\/j.blre.2026.101436_bb0540","series-title":"Abstract presented at: ESH-iCMLf 27th annual John Goldman conference on chronic myeloid leukemia: Biology and therapy; October 12-15","article-title":"Olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)","author":"Li","year":"2025"},{"key":"10.1016\/j.blre.2026.101436_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00354-5","article-title":"Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1\/2 trial","volume":"12","author":"Cortes","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101436_bb0550","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101436_bb0555","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:39:32Z","timestamp":1792010372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":111,"alternative-id":["S0268960X26000755"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101436","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101436"}}